List of Excipients in Branded Drug EXELDERM

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Journey Medical Corporation	EXELDERM	sulconazole nitrate	69489-711	ASCORBYL PALMITATE
Journey Medical Corporation	EXELDERM	sulconazole nitrate	69489-711	CETYL ALCOHOL
Journey Medical Corporation	EXELDERM	sulconazole nitrate	69489-711	GLYCERYL MONOSTEARATE

EXELDERM Excipient Strategy and Commercial Opportunities for Sulconazole Nitrate

Last updated: August 19, 2026

Exelderm contains sulconazole nitrate, a topical imidazole antifungal supplied as a 1% cream and 1% solution. Its commercial opportunity is primarily a formulation and lifecycle-management opportunity rather than a novel-molecule patent opportunity. The strongest development paths are differentiated vehicles, improved tolerability, better adherence, authorized-generic supply, and targeted dermatology products for fungal infections.

What is Exelderm and which dosage forms does it contain?

Exelderm is a prescription topical antifungal containing sulconazole nitrate. The labeled indications include tinea corporis, tinea cruris, tinea pedis, tinea versicolor, and cutaneous candidiasis.[1]

Product	Active ingredient	Strength	Route	Primary formulation concept
Exelderm cream	Sulconazole nitrate	1%	Topical	Emulsion cream
Exelderm solution	Sulconazole nitrate	1%	Topical	Hydroalcoholic or glycol-based solution

The product is an older topical anti-infective. Sulconazole is not a biologic, does not require biosimilar development, and does not depend on a complex-device delivery system. The key technical issues are drug solubility, skin deposition, irritation, cosmetic acceptability, microbial preservation, and equivalence to the reference product.

What excipients are used in Exelderm formulations?

The Exelderm cream label identifies a conventional topical cream base that includes cetyl alcohol, stearyl alcohol, polysorbate 60, propylene glycol, and purified water.[1] The solution uses a simpler vehicle based on solvents such as propylene glycol, alcohol, and water, subject to the applicable product labeling.

Exelderm cream excipient functions

Excipient	Formulation function	Commercial relevance
Cetyl alcohol	Consistency agent, emollient, co-emulsifier	Supports cream structure and skin feel
Stearyl alcohol	Consistency agent, emollient, co-emulsifier	Improves viscosity and body
Polysorbate 60	Nonionic emulsifier	Stabilizes the oil-in-water cream
Propylene glycol	Solvent, humectant, penetration-supporting vehicle	Can improve drug distribution but may irritate sensitive skin
Purified water	Continuous phase	Supports cream texture and application
pH adjusters or processing aids	pH and physical stability control	Affect API stability and skin tolerability

The cream architecture is conventional and potentially reproducible by generic manufacturers. Its commercial value lies less in excipient novelty than in the performance profile produced by the complete vehicle.

Exelderm solution excipient functions

The solution format is more dependent on solvent selection and precipitation control. Propylene glycol can improve sulconazole nitrate solubilization and skin residence. Alcohol can improve drying time and initial spreading, but it may increase stinging, dryness, and flammability concerns.

A solution may be attractive for hairy or intertriginous areas because it can spread without the occlusive feel associated with a cream. A cream may be more acceptable for dry, scaly lesions because it supplies emollience and reduces post-application roughness.

What excipient strategy is most commercially attractive for sulconazole nitrate?

The most attractive strategy is to maintain the 1% sulconazole nitrate strength while improving one or more of four attributes:

1. Lower irritation.
2. Faster and cleaner application.
3. Improved adherence.
4. Better lesion-site drug deposition.

A reformulator should avoid unnecessary excipient complexity. Each additional surfactant, preservative, fragrance, or penetration enhancer increases the risk of irritation, sensitization, stability failure, or regulatory bridging requirements.

Strategy 1: Low-irritancy cream

A modern low-irritancy cream could reduce reliance on volatile alcohols and minimize sensitizing preservatives. Candidate design principles include:

• Nonionic emulsification.
• Reduced fragrance and allergen content.
• Moderate propylene glycol concentration.
• Controlled pH near the skin-compatible range.
• A non-greasy emollient phase.
• Preservative selection supported by challenge testing.
• Use of highly purified, low-peroxide excipients.

This approach could support dermatology and pediatric positioning, although pediatric claims would require appropriate clinical evidence.

Strategy 2: Fast-drying solution

A fast-drying solution could target tinea pedis, tinea cruris, and lesions in hairy areas. The formulation should balance evaporation with adequate residence time. Excessive alcohol may create poor patient experience, especially on fissured skin.

Potential improvements include:

• A reduced-alcohol or alcohol-free system.
• Glycol-based solubilization.
• A low-viscosity film-forming polymer.
• Metered dispensing to reduce waste.
• Packaging that limits evaporation and contamination.

A film-forming solution may create a patentable formulation platform if it demonstrates a measurable improvement in persistence, dosing frequency, or clinical outcome. The patent position would depend on the specific polymer, solvent ratios, manufacturing process, and performance data.

Strategy 3: Spray or foam delivery

A spray could improve application to feet, large affected areas, or difficult-to-reach sites. A foam could reduce rubbing and improve cosmetic acceptance. These formats introduce development risks:

• Dose uniformity across the spray pattern.
• Propellant or pump compatibility.
• Container closure integrity.
• Flammability, if alcohol is used.
• Drug crystallization during storage.
• Demonstration of equivalent skin exposure.

A spray or foam would likely create a more defensible product position than a simple excipient substitution, but the development cost would be higher.

Strategy 4: Barrier-compatible formulation

Patients with tinea pedis or intertriginous fungal infections may have compromised skin barriers. A vehicle that limits dehydration and irritation could improve adherence. Candidate excipient classes include non-occlusive emollients, humectants, and skin-compatible lipids.

The main risk is reducing drug release from the vehicle. A more occlusive base can improve hydration but may change sulconazole partitioning and local bioavailability. Release testing, drug crystallinity analysis, and comparative clinical performance would be required.

What formulation patents could protect an improved Exelderm product?

The original Exelderm cream and solution are legacy formulations. Broad claims covering sulconazole nitrate in a topical cream or solution would face substantial prior-art risk. Commercially meaningful protection would more likely come from narrow claims covering a defined formulation or delivery system.

Potential patent categories include:

Patent category	Possible claim focus	Relative strength
Composition	Specific solvent, emulsifier, polymer, lipid, or preservative ranges	Moderate if supported by unexpected performance
Drug-release profile	Defined release or skin-deposition characteristics	Moderate to strong with validated data
Low-irritancy formulation	Narrow excipient combination linked to tolerability	Moderate
Spray or foam	Device-formulation combination and dose delivery	Moderate to strong
Manufacturing process	Solubilization, homogenization, cooling, or crystallization control	Moderate
Packaging	Container that preserves concentration or prevents evaporation	Usually narrow
Method of use	Reduced dosing frequency or specific patient population	Potentially useful but evidence-intensive

A patent application based only on substituting one conventional emulsifier for another would face obviousness challenges. A stronger filing would connect the formulation to a demonstrated technical effect, such as improved sulconazole skin deposition without higher irritation, a stable supersaturated system, or materially longer residence time.

When does Exelderm lose exclusivity and what is its Orange Book status?

Sulconazole nitrate and the conventional Exelderm dosage forms are legacy products. Any original new-drug patent or regulatory exclusivity associated with the product would have expired long ago. The relevant competitive question is therefore not loss of primary-molecule exclusivity but the current status of approved products, listed patents, authorized generics, and abbreviated applications.

Topical products may have a more complicated regulatory record than oral solid dosage forms. FDA approval pathways can depend on the product’s regulatory classification, reference listed drug status, dosage form, and the availability of an FDA-recognized bioequivalence approach.[2]

The Orange Book should be checked for:

• The current reference listed drug.
• Any active listed patents.
• Paragraph IV certifications.
• Pediatric exclusivity.
• Therapeutic-equivalence codes.
• Approved cream and solution products.

A legacy topical product may have no meaningful active patent barrier even if the reference product remains listed. Orange Book status does not by itself establish commercial availability, manufacturing continuity, or the absence of formulation patents outside the listed patent record.[2]

Are there Paragraph IV challenges or generic entry risks for Exelderm?

Generic entry risk is high for a conventional sulconazole nitrate cream or solution if an approved reference product and an acceptable regulatory pathway are available. The key barriers are technical and regulatory rather than patent-based.

Generic entry risks

Risk	Impact on development
Lack of current reference-product supply	Can delay comparative testing
Complex or poorly characterized vehicle	Raises formulation-development cost
Unclear topical bioequivalence pathway	May require additional clinical or dermatopharmacokinetic work
API solubility and crystallization	Can cause batch variability
Preservative effectiveness	Requires robust microbiological validation
Low market size	May limit return on investment
Pharmacy substitution rules	Affect uptake after approval

A Paragraph IV challenge would matter only if an active listed patent covered the reference product. For an older product, a generic applicant may instead pursue a non-infringement or invalidity position, or develop a product that avoids any remaining listed claims.

What is the strongest commercial opportunity for Exelderm?

The strongest opportunity is a low-cost, differentiated topical antifungal platform rather than a direct cream copy. The following products have the clearest commercial logic:

Authorized generic or supply-continuity product

An authorized generic can compete on price, wholesaler access, and supply reliability. This route has limited differentiation and depends on securing rights from the product owner or an approved manufacturing relationship.

Improved cream for sensitive skin

A preservative-minimized, fragrance-free cream could target patients who discontinue topical antifungals because of burning, dryness, or poor cosmetic feel. The product would need clinical or human-factors evidence to support claims beyond simple ingredient labeling.

Alcohol-reduced solution

A low-sting solution could compete against conventional alcohol-containing products. The value proposition would be strongest for fissured feet, intertriginous areas, and recurrent users.

Spray or foam

A spray or foam could improve reach and reduce hand contact. This format may obtain stronger retail and prescribing differentiation, particularly if it supports once-daily dosing or a cleaner application profile.

Combination or adjunctive dermatology product

A sulconazole-based product combined with a barrier-supporting or anti-inflammatory strategy could address mixed symptom burdens. Combination products raise regulatory and safety complexity. Unnecessary corticosteroid combinations would carry additional risks, including masking infection and promoting inappropriate use.

How does Exelderm compare with competing topical antifungals?

Sulconazole competes with azole products such as clotrimazole, miconazole, econazole, ketoconazole, and newer agents such as luliconazole and efinaconazole in adjacent indications. Terbinafine is a major non-azole competitor for dermatophyte infections.

Product class	Commercial advantage	Formulation opportunity
Sulconazole	Established topical azole; cream and solution heritage	Improved tolerability and delivery
Clotrimazole	Broad availability and low cost	Convenience, cosmetic profile
Miconazole	Retail familiarity and broad distribution	Preservative and vehicle differentiation
Terbinafine	Strong dermatophyte positioning and short courses	Adherence and delivery format
Luliconazole	Modern branded positioning and low-frequency dosing	Premium pricing, but higher competition
Efinaconazole	Specialized solution delivery for nails	Device and penetration technology

Sulconazole is unlikely to win a premium position through molecule identity alone. A commercially viable product must offer a clear advantage in application, tolerability, dosing frequency, packaging, or supply reliability.

What manufacturing and intellectual-property barriers affect sulconazole formulations?

The main manufacturing barriers are control of API distribution, prevention of crystallization, emulsion stability, microbial control, and batch-to-batch rheology.

Critical manufacturing controls

• API particle-size distribution.
• Sulconazole nitrate polymorph or solid-state form.
• Order of excipient addition.
• Temperature during emulsification and cooling.
• Homogenization energy and duration.
• Final pH.
• Viscosity and spreadability.
• Preservative concentration and effectiveness.
• Filling temperature and tube compatibility.
• Stability under accelerated and long-term conditions.

The most defensible manufacturing patent would cover a process that solves a documented problem, such as reducing API crystallization or producing consistent drug loading at commercial scale. Process claims should be supported by comparative batches and analytical data.

Geographic coverage should prioritize the United States, European Union, Japan, Canada, Australia, and selected emerging markets with established topical antifungal demand. For a low-price generic, global filing costs may exceed the value of broad geographic patent coverage. For a premium spray, foam, or film-forming product, a broader international filing strategy may be justified.

What regulatory pathway applies to a new Exelderm formulation?

A direct generic cream or solution would generally pursue an abbreviated pathway when the product and regulatory reference are eligible. A materially different dosage form, delivery system, or clinical claim may require a more complex submission.

FDA development should address:

• Pharmaceutical equivalence.
• Active-ingredient identity and strength.
• Inactive-ingredient comparability.
• In vitro release.
• Product quality and stability.
• Microbiological quality.
• Local tolerability.
• Comparative dermatopharmacokinetics or clinical efficacy, where required.
• Container-closure performance.
• Labeling consistency.

FDA topical dermatology guidance emphasizes product quality, formulation characterization, and appropriate in vitro or in vivo performance evidence.[3] The regulatory burden rises when a new vehicle materially changes drug release, skin penetration, dosing frequency, or the treatment population.

Key Takeaways

• Exelderm is a legacy sulconazole nitrate topical antifungal supplied in cream and solution formats.
• Its conventional excipients offer limited standalone patent value.
• The best commercial opportunities are low-irritancy cream, reduced-alcohol solution, spray, foam, and film-forming delivery.
• Generic entry risk is high for a conventional copy if a viable regulatory reference and supply chain exist.
• The strongest new patent position would rely on a defined excipient system tied to improved skin deposition, stability, tolerability, or dosing convenience.
• Original molecule-level exclusivity is not the principal barrier for sulconazole.
• Manufacturing control of crystallization, emulsion stability, preservative performance, and viscosity is central to product quality.
• Commercial success depends on differentiation against terbinafine, clotrimazole, miconazole, luliconazole, and other topical antifungals.

Frequently Asked Questions

Can propylene glycol be removed from an Exelderm cream?

Yes, but removal may reduce sulconazole solubilization, alter release, and change skin deposition. A replacement solvent or co-solvent system would require comparative formulation and stability testing.

Is a sulconazole spray likely to receive patent protection?

It may receive protection if the spray has a novel composition, dose-delivery mechanism, stability profile, or demonstrated skin-deposition advantage. A conventional pump spray with routine excipients would face a weaker patent position.

Does Exelderm qualify for biosimilar competition?

No. Sulconazole nitrate is a small-molecule active ingredient. Competition would arise through generic or other abbreviated pharmaceutical pathways, not biosimilar development.

What excipient is most likely to cause tolerability concerns?

Propylene glycol and alcohol-containing vehicles can cause burning or irritation in some users, especially on fissured or inflamed skin. Surfactants and preservatives can also contribute to irritation or sensitization.

Can a new Exelderm formulation support once-daily dosing?

Possibly, but once-daily use would require evidence that the new vehicle maintains adequate antifungal activity and skin exposure with reduced application frequency. The claim would need regulatory and clinical support.

References

1. DailyMed. (n.d.). Exelderm: Sulconazole nitrate cream and solution prescribing information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

3. U.S. Food and Drug Administration. (2022). Draft guidance for industry: Topical dermatologic drug products (nonsterile) - product quality. https://www.fda.gov/regulatory-information/search-fda-guidance-documents